ASSET PURCHASE AGREEMENT by and among KING PHARMACEUTICALS, INC. MONARCH PHARMACEUTICALS, INC., PARKEDALE PHARMACEUTICALS, INC., and KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. as Sellers JHP PHARMACEUTICALS, LLC as Buyer dated as of July 14, 2007Asset Purchase Agreement • July 19th, 2007 • King Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Asset Purchase Agreement (this “Agreement”) is made and entered into as of July 14, 2007 (the “Effective Date”), by and between JHP Pharmaceuticals, LLC, a Delaware limited liability company (“Buyer”), and King Pharmaceuticals, Inc., a Tennessee corporation (“King”), Monarch Pharmaceuticals, Inc., a Tennessee corporation (“Monarch”), Parkedale Pharmaceuticals, Inc., a Michigan corporation (“Parkedale”) and King Pharmaceuticals Research and Development, Inc., a Delaware corporation (“King R&D”) (King, Monarch, Parkedale and King R&D referred to herein collectively as “Sellers” and each as a “Seller”).
